Featured Research

from universities, journals, and other organizations

Research points to two promising proteins for preventing diabetes

Date:
May 25, 2010
Source:
Indiana University School of Medicine
Summary:
Two human proteins that evolutionary processes have conserved from ancient single-celled organisms appear to provide new targets of opportunity for scientists hoping to thwart the development of diabetes.

Two human proteins that evolutionary processes have conserved from ancient single-celled organisms appear to provide new targets of opportunity for scientists hoping to thwart the development of diabetes.

In experiments using diabetes-prone mice, blocking the actions of the proteins significantly reduced the development of diabetes in the mice. The findings were reported by a multi-institutional research team led by Raghu Mirmira, M.D., Ph.D., associate professor of pediatrics at the Indiana University School of Medicine, and were published online May 24 and will appear in the June 2010 issue of the Journal of Clinical Investigation.

More than 23 million Americans have been diagnosed with diabetes, which is one of the leading causes of the death in the United States. Diabetes can occur when the body is unable to produce enough insulin, or when it loses its ability to respond properly to the production of insulin, a hormone the body uses to convert food into energy. No matter the cause, research suggests that inflammatory processes contribute to the development of diabetes.

One of the proteins targeted in the research, eIF5A, is believed to be involved with inflammation processes, but its activities had not been studied in the pancreas islet cells that produce insulin. The research team looked at eIF5A because its corresponding gene sits near other inflammation-related genes in both the mouse and human genomes, said Dr. Mirmira, director of the Pediatric Diabetes Research Group at the Herman B Wells Center for Pediatric Research, on the campus of Indiana University-Purdue University, Indianapolis.

"Because it sat in a hotbed of inflammatory genes, and because many of these inflammatory genes are known to be important in the progression of diabetes, we thought eIF5A might also have role in the progression of diabetes," Dr. Mirmira said.

But eIF5A doesn't act on its own. Instead, another protein, an enzyme called DHS, is necessary to activate eIF5A -- in fact it appears that the sole role of DHS is to activate eIF5A.

"So our underlying premise was that if eIF5A is crucial in inflammation, and DHS is crucial in activating eIF5A, then inhibiting DHS should block eIF5A," Dr. Mirmira said.

The researchers used two different approaches to block the activity of eIF5A. In one, they constructed a special genetic molecule called a small interfering RNA -- siRNA -- designed to disrupt the production of eIF5A in the islet cells within a living mouse. The second approach used a compound, GC7, that inhibits the production of DHS. Both approaches gave similar results -- that the development of diabetes can be blocked in a mouse -- but the DHS approach seems to offer a more promising route to possible treatments because no therapies have yet been approved using siRNA technologies.

"What this study has done is identify what we believe is a new target that could be amenable to a drug therapy," said Dr. Mirmira. A next step would be to further illuminate the role of eIF5A in the normal development of diabetes, in contrast to the experimental models used in this research, he said.

Support for the research was provided by National Institutes of Health, Senesco Technologies Inc. and the Ball Brothers Foundation.


Story Source:

The above story is based on materials provided by Indiana University School of Medicine. Note: Materials may be edited for content and length.


Journal References:

  1. bernhard Maier, Takeshi Ogihara, Anthony P. Trace, Sarah A. Tersey, Reiesha D. Robbins, Swarup K. Chakrabarti, Craig S. Nunemaker, Natalie D. Stull, Catherine A. Taylor, John E. Thompson, Richard S. Dondero, Eli C. Lewis, Charles A. Dinarello, Jerry L. Nadler and Raghavendra G. Mirmira. The unique hypusine modification of eIF5A promotes islet β cell inflammation and dysfunction in mice. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI38924
  2. Joachim Hauber. Revisiting an old acquaintance: role for eIF5A in diabetes. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI43237

Cite This Page:

Indiana University School of Medicine. "Research points to two promising proteins for preventing diabetes." ScienceDaily. ScienceDaily, 25 May 2010. <www.sciencedaily.com/releases/2010/05/100524173721.htm>.
Indiana University School of Medicine. (2010, May 25). Research points to two promising proteins for preventing diabetes. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2010/05/100524173721.htm
Indiana University School of Medicine. "Research points to two promising proteins for preventing diabetes." ScienceDaily. www.sciencedaily.com/releases/2010/05/100524173721.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins